Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU

  • Posted by: Biocon Biologics

Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for Semglee™ Biosimilar Insulin Glargine

  • Posted by: Biocon Biologics

Update on Company Statement on US-FDA Inspection at Biocon Malaysia

  • Posted by: Biocon Biologics

Company Statement on US-FDA Inspection at Biocon Malaysia

  • Posted by: Biocon Biologics

Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine

  • Posted by: Biocon Biologics

Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore

  • Posted by: Biocon Biologics

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

  • Posted by: Biocon Biologics

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

  • Posted by: Biocon Biologics

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers

  • Posted by: Biocon Biologics

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

  • Posted by: Biocon Biologics
Share